X HC 215783#SR-16977 Blue X HC 215783#SR-16971 Pink X HC 215783#SR-16974 Gray

X GT-15194-01 X GT-15194-02 X GT-15991-1A

X GT-13563-1C X GT-13563-1D X GT-13563-1E

X ND1200 PLT X ET-37-EC-1-2 X SR-25759-B3

X ST 14462-001-1 X ST 14462-001-2 X ST 14462-001-3

These investments also consider our global footprint, and we are positioned very well and strategically from a regional perspective. 8 Growth Drivers 2020 Revenue ($ Millions) Long-Term Growth Rate Sustainable Solutions $ 560 8–12% Healthcare 555 8–10% Composites / 5G 212 10% Growth in Emerging Regions 672 5% Other (GDP growth) 1,784 2–3% Pro Forma Avient $ 3,783 6.5% 2 0 2 0 P E R F O R M A N C E 2020 HIGHLIGHTS 10 • Completed transformational Clariant Masterbatch acquisition and created new brand name Avient • Increased pro forma adjusted EPS 11% from $1.74 to $1.93 as an essential supplier during the pandemic and due to growth in demand for consumer applications • Specialty Engineered Materials delivered record operating income on gains from composites • Achieved record free cash flow, increased dividend for 10th year in a row and delevered from 3.5x to 2.7x net debt to pro forma adjusted EBITDA • Culture is everything: Certified as a Great Place to Work® $133 $150 2019PF 2020PF 10% 23%8% 21% 4% 15% 2006 2020PF Healthcare Consumer Packaging Avient Portfolio Transformation 22% 59% CLARIANT MASTERBATCH: TRANSFORMATIONAL ACQUISITION 11 Clariant MB EBITDA Growth Purchase Price Multiple 10.8 9.6 6.5 2019PF 2020PF 2020PF w/ Full Synergies x x x • Acquisition of Clariant Masterbatch significantly expands presence in healthcare, packaging and consumer end markets • Strength of portfolio – 13% EBITDA growth as an essential supplier in COVID response and recovery • Acquisition completed on July 1, 2020 for $1.4 billion. D is t. ) K W R R P M P P G A V Y F U L G C P F M C H X L IF F F O E H U N E C L K R A E M N A S H C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of March 12, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi e n t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.

Immediately accretive to EPS, the acquisition is expected to deliver $0.95 of incremental adjusted EPS upon full synergy realization. 14 (1) 2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business (2) Adjusted EPS excludes step up D&A for the Clariant Masterbatch acquisition (3) Assumes $75MM in synergies E B I T DA M a r g i n E x p a n s i o n a n d E P S A c c r e t i o n 11.9% 14.2% 17.1% Avient PF Avient PF ex. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 17 Capex / Revenue 2021E (%) Source: Bloomberg market data as of November 9, 2020 AV I E N T I S A S S E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 3 3 3 6 3 4 5 5 5 5 5 6 6 7 7 9 24 A v ie n t A v ie n t (E x c l. D is t. ) R P M K W R P P G F U L A V Y G C P F M C IF F H X L H U N F O E E M N E C L S C L K R A A S H C E G R A A L B Median: 5%Median: 3% Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators.

Autoinjector Pen - Avient Application Study.mm (1) AUTO-INJECTOR APPLICATION STUDY M A T E R I A L T E C H N O L O G I E S + S E R V I C E S F O R N E X T G E N E R A T I O N D E S I G N S Avient Corporation 1 Avient Corporation 2 Innovating Design Medical innovations and plastics have gone hand-in-hand to make healthcare safer, cleaner, and more accessible for all. Pigments and eye-catching special effects • Prompt, precise and custom color matching • Biocompatible functional additives • FDA CFR 21, USP VI, ISO 10993-X, and/or USP 661-X • ISO 13485 facilities Avient Corporation 5 4.

PP NONWOVEN MANUFACTURER G E O T E X T I L E S • High concentrate UV solution (up to 50% light protection) in PP nonwoven textiles • Shorter lead time from existing supplier • Local technical support • Long-lasting UV stability • Provided high concentrate UV protection in nonwoven textiles with dosage @ 50% • Shortened the lead time with global supply and technical service • Offered excellent UV stability CesaTM Light Additives KEY REQUIREMENTS WHY AVIENT?

LU X U RY PAC K AG IN G M A NUFAC TUR ER S P I R I T B O T T L E C A P S • Specific gravity of 1.6 • EU and FDA compliant material • ABS-based material suitable for electroplating • Delivered a customized density polymer that supported electroplating, resulting in both the look and feel of metal • Demonstrated experience and expertise in density-modified material technology and electroplating to reach application goals quickly and cost-effectively Gravi-Tech™ Density Modified Formulation KEY REQUIREMENTS WHY AVIENT?